Ozempic vs. Mounjaro:: Battle of the bulge

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers…

#glp1 #novonordiskasnyse #nvosemaglutide #ozempic #novonordisk #fda #obese #ww #teladochealthinc #tdoc